Neurohormonal Parameters in Hypertrophic Cardiomyopathies (REEF-CMH)

French Cardiology Society

Status

Completed

Conditions

3- Non Obstructive Hypertrophic Cardiomyopathy

2- Obstructive Hypertrophic Cardiomyopathy

1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy

Treatments

Other: blood sample collection

Study type

Interventional

Funder types

Other

Identifiers

NCT01729702

2008-08

Details and patient eligibility

About

The primary purpose of this study is to demonstrate that changes in plasma levels of circulating neurohormones (mainly BNP and NT-proBNP), measured at rest and post-exercise correlate with exercise functional limitation (assessed by exercise peak VO2) and exercise ultrasonic parameters (as left ventricular filling, obstruction, and mitral regurgitation)

Full description

The secondary purposes are to study the kinetics of secretions of natriuretic peptides, and their relationships with extent of MRI myocardial fibrosis with the degree of exercise functional limitation.

Enrollment

131 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

- Age 18 to 75 years
Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive, with studies of exercise peak oxygen consumption and cardiac MRI with gadolinium late-enhancement
Informed consent
Patient with a social insurance Patient at rest
- Age 18 to 75 years
Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive
Informed consent
Patient with a social insurance

Exclusion criteria

- Insufficient echogenicity
Permanent atrial fibrillation
Complete BBB on the ECG
LVEF < 35 %
Previous septal ablation (surgical or percutaneous)
Simultaneous participation to another biomedical research

If exercise needed:

contraindication to exercise : hemodynamic instability, uncontrolled high blood pressure (>220/120 mmHg), severe aortic stenosis
Inability to exercise (muscular, pulmonary, elderly patient)